Toso regulates the balance between apoptotic and nonapoptotic death receptor signaling by facilitating RIP1 ubiquitination

Blood

Volumn 118, Issue 3, 2011, Pages 598-608

  Nguyen, Xuan Hung ^a   Lang, Philipp A ^b   Lang, Karl S ^c   Adam, Dieter ^d   Fattakhova, Gulnar ^a   Föger, Niko ^a   Kamal, Mohammad Azhar ^a   Prilla, Patricia ^a   Mathieu, Sabine ^d   Wagner, Christina ^a   Mak, Tak ^b   Chan, Andrew C ^e   Lee, Kyeong Hee ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; DEATH RECEPTOR; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; PROTEIN KINASE; PROTEIN RIP1; PROTEIN TOSO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL SURVIVAL; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LIVER INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 79960657818     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-10-313643     Document Type: Article

References (36)

1. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995;14(22):5579-5588.
2. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003;10(1):26-35. (Pubitemid 36511830)
3. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet. 1999;33:29-55. (Pubitemid 30083118)
4. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356(6367):314-317.
5. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268(5215):1347-1349.
6. Lee KH, Feig C, Tchikov V, et al. The role of receptor internalization in CD95 signaling. EMBO J. 2006;25(5):1009-1023. (Pubitemid 43372115)
7. Peter ME, Budd RC, Desbarats J, et al. The CD95 receptor: apoptosis revisited. Cell. 2007;129(3):447-450. (Pubitemid 46660984)
8. Hao Z, Hampel B, Yagita H, Rajewsky K. T cell-specific ablation of Fas leads to Fas ligand-mediated lymphocyte depletion and inflammatory pulmonary fibrosis. J Exp Med. 2004;199(10):1355-1365. (Pubitemid 38685727)
9. O'Reilly LA, Tai L, Lee L, et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature. 2009;461(7264):659-663.
10. Hitoshi Y, J. Lorens SIKitada, et al. Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity. 1998;8(4):461-471. (Pubitemid 28196800)
11. Kubagawa H, Oka S, Kubagawa Y, et al. Identity of the elusive IgM Fc receptor (FcμR) in humans. J Exp Med. 2009;206(12):2779-2793.
12. Abbas AR, Baldwin D, Ma Y, et al. Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun. 2005;6(4):319-331. (Pubitemid 40903405)
13. Pallasch CP, Schulz A, Kutsch N, et al. Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. Blood. 2008;112(10):4213-4219.
14. Proto-Siqueira R, Panepucci RA, Careta FP, et al. SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood. 2008;112(2):394-397.
15. Ting AT, Pimentel-Muiños FX, Seed B. RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. EMBO J. 1996;15(22):6189-6196. (Pubitemid 26397891)
16. Holler N, Zaru R, Micheau O, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2000;1(6):489-495.
17. Vercammen D, Beyaert R, Denecker G, et al. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med. 1998;187(9):1477-1485. (Pubitemid 28215406)
18. Christofferson DE, Yuan J. Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol. 2010;22(2):263-268.
19. Song Y, Jacob CO. The mouse cell surface protein TOSO regulates Fas/Fas ligand-induced apoptosis through its binding to Fas-associated death domain. J Biol Chem. 2005;280(10):9618-9626. (Pubitemid 40409658)
20. Varfolomeev E, Maecker H, Sharp D, et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem. 2005;280(49):40599-40608. (Pubitemid 41780550)
21. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, P. Leder. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity. 1998;8(3):297-303. (Pubitemid 28188890)
22. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell. 2006;22(2):245-257.
23. O'Donnell MA, Legarda-Addison D, Skountzos P, Yeh WC, Ting AT. Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF signaling. Curr Biol. 2007;17(5):418-424.
24. Bertrand MJ, Milutinovic S, Dickson KM, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell. 2008;30(6):689-700. (Pubitemid 351818251)
25. Lee TH, Shank J, Cusson N, Kelliher MA. The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J Biol Chem. 2004;279(32):33185-33191. (Pubitemid 39062963)
26. Li H, Kobayashi M, Blonska M, You Y, Lin X. Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappaB activation. J Biol Chem. 2006;281(19):13636-13643. (Pubitemid 43855279)
27. Legembre P, Barnhart BC, Zheng L, et al. Induction of apoptosis and activation of NF-kappaB by CD95 require different signalling thresholds. EMBO Rep. 2004;5(11):1084-1089. (Pubitemid 39600208)
28. Devin A, Lin Y, Liu ZG. The role of the death-domain kinase RIP in tumour-necrosis-factor-induced activation of mitogen-activated protein kinases. EMBO Rep. 2003;4(6):623-627. (Pubitemid 36939955)
29. Stanger BZ, Leder P, Lee TH, Kim E, Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell. 1995;81(4):513-523.
30. Sabbagh L, Snell LM, Watts TH. TNF family ligands define niches for T cell memory. Trends Immunol. 2007;28(8):333-339. (Pubitemid 47077923)
31. Kim EY, Teh H-S. TNF Type 2 Receptor (p75) lowers the threshold of T cell activation. J Immunol. 2001;167(12):6812-6820. (Pubitemid 33144172)
32. Bradham CA, Plumpe J, Manns MP, Brenner DA, Trautwein C. Mechanisms of hepatic toxicity I: TNF-induced liver injury. Am J Physiol. 1998;275(3 Pt 1):G387-G392.
33. Chatzidakis I, Mamalaki C. T cells as sources and targets of TNF: Implications for immunity and autoimmunity. Curr Dir Autoimmun. 2010;11:105-118.
34. Swain MG. Natural killer T cells within the liver: Conductors of the hepatic immune orchestra. Dig Dis. 2010;28(1):7-13.
35. Tiegs G. T cells, NKT cells, and NK cells in an experimental model of autoimmune hepatitis. In: Gershwin ME, Vierling JM, and Manns MP, eds. Liver Immunology. Philadelphia, PA: Hanley and Belfus; 2003:171-183.
36. Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A. 2000;97(10):5498-5503. 2